Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Efficacy and safety of abatacept (CTLA41g), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-alpha therapy: Results of the phase III ATTAIN (Abatacept trial in treatment of Anti-TNF INadequate responders) 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals Genovese, M., Luggen, M., Schiff, M., Sherrer, Y., Nuamah, I., Aranda, R., Becker, J. C., Dougados, M. WILEY-BLACKWELL. 2004: 4103–
View details for Web of Science ID 000225750200114